Skip to Main Content
Contribute Try STAT+ Today

Back in May, Novartis scrambled to contain the fallout about its relationship with President Trump’s personal attorney, Michael Cohen, who was paid $1.2 million in consulting fees to provide access and insights into the new administration.

In carefully choreographed moments, the former chief executive, Joe Jimenez, took responsibility for the “mistake,” since he agreed to the one-year deal in early 2017. And his successor, Vas Narasimhan, who began running the company this past February, had already declined to renew the contract and vowed to uphold “ethical standards.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.